Aurobindo Pharma Ltd. News and Updates

Name: Latest research reports of Aurobindo Pharma Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Aurobindo Pharma Ltd. from all sources in a single place.

Load latest

Aurobindo Pharma Ltd.

26 Oct 2020

1119.20

-0.86%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

Natrol had annual sales of US$157 million (4.8% of consolidated sales) in FY20. Hence, this transaction values the business at 3.5x sales, a compelling deal by any standards. The company will utilise proceeds to reduce debt and other new strategic initiatives. We believe a significant portion of the company's current debt (| 4777 crore as of Q1FY21) is working capital based. Therefore, a major portion of cash generated through this deal is likely be utilised for strategic investments. The sale of this non-core segment is likely to improve focus on new and complex ventures such as biosimilars,...

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1126.0

Aurobindo Pharma Ltd.

22 Oct 2020

1119.20

-0.86%

Aurobindo Pharma gets USFDA nod for generic pain killer

Business Line

Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration (USFDA) for its generic Acetaminophen injection. It is indi

Aurobindo Pharma Ltd. has lost -26.76% in the last 1 Year

Aurobindo Pharma tumbles over 3% after USFDA warning letter to subsidiary

Business Standard | 22 Oct 2020 1 more

Aurobindo Pharma Ltd.

05 Oct 2020

1119.20

-0.86%

Aurobindo Pharma: Multiple growth triggers to improve Street sentiment

Business Standard

Rebound in injectable sales, multiple product launches, strong European outlook and reduction in net debt are key earning triggers

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1126.0

Aurobindo Pharma Ltd.

28 Sep 2020

1119.20

-0.86%

Buy Aurobindo Pharma; target of Rs 1030: Motilal Oswal

Moneycontrol

Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1030 in its research report dated September 27, 2020.

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1126.0

Aurobindo Pharma Ltd.

27 Sep 2020

1119.20

-0.86%

Development of complex pipeline on track

Neutral: Aurobindo Pharma Ltd.

Recommendation Target

Motilal Oswal

27 September 2020 ARBP's future pipeline comprises differentiated and margin-accretive products in Oncology, Depot Injections, Inhalers, Biosimilars, Vaccines, Topicals, and Patches. Overall it has 6MDIs, 2 Dry Powder Inhalers (DPIs), 14 Biosimilars, 26 Topicals, 8 Transdermals, 3 Depot Injections and 2 Vaccines under development. We expect ARBP to deliver 10% sales CAGR in the US over FY20-22E. While there has been COVID-led slowdown in the EU business, ARBP remains on track to expand its product offerings, adding newer markets and increasing its penetration in existing markets. We expect ARBP to deliver 6% sales CAGR in the EU business over FY20-22E. ARBP has completed the corrective and preventive action (CAPA) at Units 1, 9, and 11/Aurolife and is awaiting feedback from the USFDA on desktop reviews. ARBP should complete the CAPA at Unit 7 soon. Aurobindo Pharma We expect ARBP to deliver 15% earnings CAGR over FY20-22E, led by new launches /increased market share in key markets of the US/EU and lower financial leverage.

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1087.9

Aurobindo Pharma Ltd.

23 Sep 2020

1119.20

-0.86%

Buy Aurobindo Pharma; target of Rs 975: Sharekhan

Moneycontrol

Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 975 in its research report dated September 22, 2020.

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1087.9

Aurobindo Pharma Ltd.

22 Sep 2020

1119.20

-0.86%

Aurobindo Pharm

Buy: Aurobindo Pharma Ltd.

Recommendation Target

Sharekhan

Aurobindo Pharma Limited (Aurobindo) is witnessing improved traction in its US business, which constitutes around half of overall sales. Aurobindo is one of the few pharmaceutical companies reporting an impressive performance in the US as compared to others, which have been facing challenges. The US business is expected to grow in double digits going ahead. A combination of factors, including a sturdy new product pipeline, easing of pricing pressures, opportunities arising from shortage of products in the US, and an expected recovery in the injectable business would be key drivers for the US business....

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

16 Sep 2020

1119.20

-0.86%

Aurobindo Pharma: Shot in the arm for Covid vaccine development programme

Moneycontrol

Vaccine capacity creation puts Aurobindo in the league of Serum institute of India and Cadila in the race for a Covid drug

Aurobindo Pharma Ltd.'s price crossed below 100Day SMA today

MARKET LIVE: Indices likely to open lower; Aurobindo Pharma in focus

Business Standard | 16 Sep 2020 5 more

Aurobindo Pharma Ltd.

07 Sep 2020

1119.20

-0.86%

Pick of the Week:07 SEP 2020

Buy: Aurobindo Pharma Ltd.

Target

Axis Direct

Aurobindo Pharma Limited (ARBP) manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological

Aurobindo Pharma Ltd.'s price crossed below 100Day SMA today

Aurobindo Pharma Ltd.

19 Aug 2020, 11:07AM

1119.20

-0.86%

Buy Aurobindo Pharma; target of Rs 1027: KR Choksey

Moneycontrol

KR Choksey is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1027 in its research report dated August 17, 2020.